助手标题  
全文文献 工具书 数字 学术定义 翻译助手 学术趋势 更多
查询帮助
意见反馈
   allogeneic bone 在 儿科学 分类中 的翻译结果: 查询用时:0.01秒
图标索引 在分类学科中查询
所有学科
儿科学
外科学
肿瘤学
口腔科学
临床医学
眼科与耳鼻咽喉科
特种医学
畜牧与动物医学
生物医学工程
更多类别查询

图标索引 历史查询
 

allogeneic bone
相关语句
  同种异体骨
    Allogeneic Bone Graft for the Treatment of Benign Bone Tumors
    同种异体骨移植治疗儿童良性骨肿瘤
短句来源
    Allogeneic bone graft in the treatment of children's bone cyst
    同种异体骨移植治疗儿童骨囊肿
短句来源
    Methods From April 1997 to May 2004 ,the author conducted a study of using γ ray irradiate allogeneic bone and reserved in cyclosporine.
    方法作者自1997—2004年采用经γ射线照射深低温储存的同种异体骨移植治疗儿童良性骨肿瘤及瘤样病变34例。
短句来源
  异体骨
    Allogeneic Bone Graft for the Treatment of Benign Bone Tumors
    同种异体骨移植治疗儿童良性骨肿瘤
短句来源
    Allogeneic bone graft in the treatment of children's bone cyst
    同种异体骨移植治疗儿童骨囊肿
短句来源
    Methods From April 1997 to May 2004 ,the author conducted a study of using γ ray irradiate allogeneic bone and reserved in cyclosporine.
    方法作者自1997—2004年采用经γ射线照射深低温储存的同种异体骨移植治疗儿童良性骨肿瘤及瘤样病变34例。
短句来源
    [Objective] The results of a percutaneous aspiration and injection of autologous bone marrow and allogeneic bone powder for giant unicameral bone cysts in children are reported.
    目的报道经皮注射自体骨髓加异体骨移植治疗儿童巨大骨囊肿的疗效。
短句来源
  同种异体骨
    Allogeneic Bone Graft for the Treatment of Benign Bone Tumors
    同种异体骨移植治疗儿童良性骨肿瘤
短句来源
    Allogeneic bone graft in the treatment of children's bone cyst
    同种异体骨移植治疗儿童骨囊肿
短句来源
    Methods From April 1997 to May 2004 ,the author conducted a study of using γ ray irradiate allogeneic bone and reserved in cyclosporine.
    方法作者自1997—2004年采用经γ射线照射深低温储存的同种异体骨移植治疗儿童良性骨肿瘤及瘤样病变34例。
短句来源
  “allogeneic bone”译为未确定词的双语例句
    Treatment of childhood leukemia with unrelated donor allogeneic bone marrow tran splantation
    非亲缘异基因骨髓移植治疗儿童白血病
短句来源
    Second transplantation using allogeneic bone marrow from parents for beta-thalassaemia major patients after graft failure
    HLA部分相合父母供髓骨髓移植二次治疗重型地中海贫血
短句来源
    [Methods] 7 cases of giant unicameral bone cysts in children were reported, The treatment included percutaneous aspiration of fluid in the bone cyst and injection of autologous bone marrow and allogeneic bone powder.
    方法对7例儿童巨大单房性骨囊肿在C臂X光机监视下经皮穿刺抽尽囊液后注入自体骨髓和异体骨粉。
短句来源
    [Conclusion] Percutaneous injection of autologous bone marrow and allogeneic bone powder appears to be an effective and simple method for giant unicameral bone cysts in children.
    结论经皮注射自体骨髓加异体骨粉移植治疗儿童巨大单房性骨囊肿是一种简单、微创、疗效确切的方法。
短句来源
查询“allogeneic bone”译词为用户自定义的双语例句

    我想查看译文中含有:的双语例句
例句
为了更好的帮助您理解掌握查询词或其译词在地道英语中的实际用法,我们为您准备了出自英文原文的大量英语例句,供您参考。
  allogeneic bone
Special risk factors analyzed are respiratory failure requiring mechanical ventilation, allogeneic bone marrow transplantation, or development of multiple organ failure.
      
To assess the cost-effect relationship of aciclovir prophylaxis versus early treatment, we performed a retrospective study in 44 allogeneic bone marrow transplant recipients, who had only received aciclovir for therapeutic purposes.
      
Infectious complications after allogeneic bone marrow transplantation with and without T-cell depletion of donor marrow
      
C-reactive protein in the management of children with fever after allogeneic bone marrow transplantation
      
This infection was acquired during a period of severe neutropenia after chemotherapy for relapsed acute myelogenous leukemia following allogeneic bone marrow transplantation.
      
更多          


Objective Allogeneic bone marrow transplantation (Allo BMT) is the most effective treatment for children with relapsed or high risk leukemia However, most patients who could benefit from Allo BMT lack an HLA identical sibling donor Using haploidentical donor for Allo BMT involves crossing HLA mismatched immunology barriers The purpose of this study was to explore the feasibility of haploidentical bone marrow transplantation in which the donors received granulocyte colony stimulating...

Objective Allogeneic bone marrow transplantation (Allo BMT) is the most effective treatment for children with relapsed or high risk leukemia However, most patients who could benefit from Allo BMT lack an HLA identical sibling donor Using haploidentical donor for Allo BMT involves crossing HLA mismatched immunology barriers The purpose of this study was to explore the feasibility of haploidentical bone marrow transplantation in which the donors received granulocyte colony stimulating factor (G CSF) prior to harvest and sequential immunomodulation added to recipient for treatment of refractory and relapsed childhood leukemia. Methods Eight patients with refractory and relapsed leukemia received a non T cell depleted Allo BMT from HLA 2 3 antigen mismatched family donors One of them suffered from acute non lymphocytic leukemia (ANLL) which was classified as a high risk, 6 suffered from acute non lymphocytic leukemia (ALL) (at CR2 or >CR2), and 1 suffered from chronic myeloid leukemia (CML) at an accelerated phase All patients were treated with a myeloablative conditioning regimen consisting of high dose cytosine arabinoside (Ara C ), cyclophosphamide (CY) and total body irradiation (TBI) Donors received G CSF (Lenograstim, Chugai Pharmaceutical ) 250 μg/d for seven days before marrow harvest A four agent graft versus host disease (GVHD) prophylaxis program consisting of cyclosporin A (CSA), methotrexate (MTX), antithymocyte globulin (ATG, Fresenius) and mycophenolate mofetial (MMF, Hoffmann Roche) had been used ATG was infused at a dose of 5 mg per kilogram daily over an eight hour period The patients received MMF orally at a dose of 1.0 g daily from day 7 to day 100. Results All patients established successful engraftment The karyotyping of chromosome and HLA analysis confirmed that they were 100% donor derived The median time when granulocyte exceeded 0 5×10 9/L and platelet exceeded 20×10 9/L was 18 days (range 16 21 days) and 19 5 days (range 17 27 days) after transplantation Acute Ⅱ Ⅳ grade of graft versus host disease (GVHD) occurred in 4 of 8 patients (50%) Two of them got acute GVHD (grade Ⅱ) and another two got acute GVHD (grade Ⅲ) Chronic GVHD was seen in all of the 5 evaluated patients (100%) and none developed extensive chronic GVHD The median follow up duration was 510 days (range 390 720 days). Three out of eight patients died Two of them died from severe acute GVHD and one died from infection Five patients were alive in disease free situation (62 5%) Conclusion The bone marrow transplantation from haploidentical donors used in this study is effective for refractory and relapsed childhood leukemia Further advances in this field will increase the availability of bone marrow transplantation as a curative therapy for childhood leukemia

目的 探讨供者应用粒细胞集落刺激因子 (G CSF)和受者联合应用多种免疫抑制剂单倍体骨髓移植治疗儿童难治复发性白血病的可行性。方法  8例难治复发性儿童白血病患儿中 ,高危急性非淋巴白血病 1例 ,急性淋巴白血病第 2次完全缓解 (CR2 )及以上的病例 6例 ,慢性粒细胞白血病加速期 1例 ,在清髓性预处理后接受单倍体供者的骨髓。供者应用G CSF 2 5 0 μg,连用 7d后采髓 ,受者移植物抗宿主病 (GVHD)的预防除环孢菌素A(CSA)和氨甲蝶呤 (MTX)外 ,在 - 4至 - 1d(移植前为“ -”)应用抗胸腺细胞球蛋白 (ATG) 5mg/ (kg·d) ,+7d(移植后为“ +”)开始加服霉酚酸酯(MMF)。结果  8例患儿均植入成功 ,中性粒细胞大于 0 5× 10 9/L和血小板大于 2 0× 10 9/L的中位天数分别是 18d(范围 16~ 2 1d)和 19 5d(范围 17~ 2 7d)。急性Ⅱ°~Ⅳ°GVHD发生 4例 (5 0 % ) ,其中 2例急性Ⅱ度肠道GVHD ,2例急性Ⅲ度肠道GVHD ,可评价的 5例患儿均发生慢性GVHD ,无一例发生广泛性慢性GVHD。中...

目的 探讨供者应用粒细胞集落刺激因子 (G CSF)和受者联合应用多种免疫抑制剂单倍体骨髓移植治疗儿童难治复发性白血病的可行性。方法  8例难治复发性儿童白血病患儿中 ,高危急性非淋巴白血病 1例 ,急性淋巴白血病第 2次完全缓解 (CR2 )及以上的病例 6例 ,慢性粒细胞白血病加速期 1例 ,在清髓性预处理后接受单倍体供者的骨髓。供者应用G CSF 2 5 0 μg,连用 7d后采髓 ,受者移植物抗宿主病 (GVHD)的预防除环孢菌素A(CSA)和氨甲蝶呤 (MTX)外 ,在 - 4至 - 1d(移植前为“ -”)应用抗胸腺细胞球蛋白 (ATG) 5mg/ (kg·d) ,+7d(移植后为“ +”)开始加服霉酚酸酯(MMF)。结果  8例患儿均植入成功 ,中性粒细胞大于 0 5× 10 9/L和血小板大于 2 0× 10 9/L的中位天数分别是 18d(范围 16~ 2 1d)和 19 5d(范围 17~ 2 7d)。急性Ⅱ°~Ⅳ°GVHD发生 4例 (5 0 % ) ,其中 2例急性Ⅱ度肠道GVHD ,2例急性Ⅲ度肠道GVHD ,可评价的 5例患儿均发生慢性GVHD ,无一例发生广泛性慢性GVHD。中位随访时间是 5 10d(范围 390~ 72 0d) ,死亡 3例 ,其中死于急性GVHD 2例 ,死于感染 1例。无病存活 5例。结论 单倍体骨髓移植治疗儿童难治复发性白血病是一种有效和安全方法 ,对我国单亲家庭拓宽供髓来源有重要的实用价值

Objective Allogeneic bone marrow transplantation (Allo BMT) has improved long term survival in children patients with refractory leukemia For patients who do not have an HLA identical sibling, the treatment option is limited Using related mismatch donors or parental donors for Allo BMT was at high risk for acute severe GVHD The purpose of this study was to explore the effects of CD25 monoclonal antibody on reducing the incidence of severe acute GVHD in haploidentical bone marrow transplantation...

Objective Allogeneic bone marrow transplantation (Allo BMT) has improved long term survival in children patients with refractory leukemia For patients who do not have an HLA identical sibling, the treatment option is limited Using related mismatch donors or parental donors for Allo BMT was at high risk for acute severe GVHD The purpose of this study was to explore the effects of CD25 monoclonal antibody on reducing the incidence of severe acute GVHD in haploidentical bone marrow transplantation for the treatment of childhood leukemia Methods Ten children with leukemia received haplotype Allo BMT from HLA two or three loci mismatched related donors Most patients were classified as in high risk category The donors of patients were given G CSF (Lenograstim Chugai) 250 μg/day for seven doses prior to marrow harvest The non T cell depleted haploidentical bone marrow was infused In addition to combination of CSA,MTX ,ATG (Fresenius Hemocare,Germany) and mycophenolate mofetil (MMF) for GVHD prophylaxis, CD 25 monoclonal antibody (Simulect, Novartis Pharma Switzerland) was administered to prevent acute severe GVHD A total of 40 mg Simulect was given in two doses of 20 mg each by 30 min intravenous infusion 2 h before transplantation and day 4 after transplantation The outcomes were compared with those of 8 children patients with leukemia who received haploidentical bone marrow transplantation without CD 25 antibody for GVHD prophylaxis Results All patients were engrafted and sustained full donor type engraftment 100% donors hematopoietic cells after transplantation was determined by cytogenetic evidence analysis The median days of granulocyte exceeding 0 5×10 9/L and pallets exceeding 20×10 9/L were 19 and 22 days, respectively Patients were monitored till up to days 100 for the sign of aGVHD None developed the grade Ⅱ Ⅳacute GVHD However, the incidence of the grade Ⅱ Ⅳ acute GVHD in control group was 50% ( P =0 0147) Eight patients could be evaluated for chronic GVHD All experienced chronic GVHD confined to the skin The median follow up duration was 12 months (range 9 24 months) Two patients died from transplant related mortality, one had patient relapsed disease and died The remaining seven patients were alive in disease free situation Conclusion The use of Simulect in haploidentical bone marrow transplantation for the treatment of children patients with leukemia is effective for preventing acute severe GVHD and may reduce transplant related mortality

目的 探讨CD2 5抗体用于预防儿童白血病半匹配未去除T细胞骨髓移植重度移植物抗宿主病 (GVHD)的疗效。方法  10例儿童白血病患者接受人类白细胞抗原 (HLA) 2~ 3个位点不合半匹配骨髓移植 ,移植方法除了供者用粒细胞集落刺激因子 (G CSF)及受者应用环孢素A(CSA)、氨甲蝶呤 (MTX)、抗胸腺细胞球蛋白 (ATG ,FreseniusHemocare ,Germany)和霉酚酸酯 (MMF)预防GVHD的综合措施外 ,加用抗CD2 5单克隆抗体 (舒莱 ,novartispharmaswitzerland)预防GVHD ,剂量各为 2 0mg ,在移植前 2h和移植后第 4天应用 ,观察移植后的疗效 ,移植结果与前期未用CD2 5抗体移植组作回顾性比较。结果  10例移植后均获造血重建 ,粒细胞 >0 5× 10 9/L的中位天数是 19d ,血小板大于 2 0× 10 9/L的中位天数是 2 2d ,骨髓植活直接证据检测证实为完全供者造血。无一例发生急性Ⅱ~Ⅳ度GVHD ,未用CD2 5抗体对照组 8例中发生急性Ⅱ~Ⅳ度GVHD有 4例 ,差异有显著性(P =0 0 14 7)。可评...

目的 探讨CD2 5抗体用于预防儿童白血病半匹配未去除T细胞骨髓移植重度移植物抗宿主病 (GVHD)的疗效。方法  10例儿童白血病患者接受人类白细胞抗原 (HLA) 2~ 3个位点不合半匹配骨髓移植 ,移植方法除了供者用粒细胞集落刺激因子 (G CSF)及受者应用环孢素A(CSA)、氨甲蝶呤 (MTX)、抗胸腺细胞球蛋白 (ATG ,FreseniusHemocare ,Germany)和霉酚酸酯 (MMF)预防GVHD的综合措施外 ,加用抗CD2 5单克隆抗体 (舒莱 ,novartispharmaswitzerland)预防GVHD ,剂量各为 2 0mg ,在移植前 2h和移植后第 4天应用 ,观察移植后的疗效 ,移植结果与前期未用CD2 5抗体移植组作回顾性比较。结果  10例移植后均获造血重建 ,粒细胞 >0 5× 10 9/L的中位天数是 19d ,血小板大于 2 0× 10 9/L的中位天数是 2 2d ,骨髓植活直接证据检测证实为完全供者造血。无一例发生急性Ⅱ~Ⅳ度GVHD ,未用CD2 5抗体对照组 8例中发生急性Ⅱ~Ⅳ度GVHD有 4例 ,差异有显著性(P =0 0 14 7)。可评价慢性GVHD的 8例均发生慢性GVHD ,为局限性慢性GVHD。中位随访 12个月 (范围 9~ 2 4个月 ) ,2例为移植相关死亡 ,1例移植后 14个月因复发死亡 ,实际无病生存率是70 %。结论 儿童半匹配未去除T细胞骨髓移植中应用舒莱 ,明显降低急性重症GVHD发生 ,临床

Objective Allogeneic bone m ar row transplantation has been established as a standard method for the treatment of a range of malignant and non-malignant hematologic diseases in children. Un fortunately, fewer than 30% of patients have a human leukocyte antigen (HLA)-ma tched sibling. Advances in our understanding of the HLA system and the developm ent of large international donor registries encourage the increasing use of unre lated donors as an alternative source of stem cells. The purpose of this study...

Objective Allogeneic bone m ar row transplantation has been established as a standard method for the treatment of a range of malignant and non-malignant hematologic diseases in children. Un fortunately, fewer than 30% of patients have a human leukocyte antigen (HLA)-ma tched sibling. Advances in our understanding of the HLA system and the developm ent of large international donor registries encourage the increasing use of unre lated donors as an alternative source of stem cells. The purpose of this study was to evaluate the clinical efficacy and safety of unrelated donor allogeneic b one marrow transplantation (URD-BMT) for the treatment of childhood leukemia. Methods Six patients with leukemia received URD-BMT. Tw o of them suffered from chronic myeloid leukemia (CML), 3 suffered from acute ly mphocytic leukemia (ALL) and 1 suffered from acute promyelocytic leukemia (APL) (CR2). All cases were facilitated by Tzu Chi Marrow Donor Registry (TCTMDR). T he high resolution DNA test for classⅠand Ⅱ was carried out in HLA typing of a ll donor-receiver pairs. HLA allele matched in three cases, mismatched with on e locus in two cases and with two loci in one case. All patients were prepared with cyclophosphamide (CY) 60 mg/kg/day for 2 days (total dose 120 mg/kg) and bu sulfan (Bu) 1 mg/kg×4/day for 4 days (total dose 16 mg/kg). Mycophenolate mofe til (MMF), CsA and MTX were given to prevent acute graft-versus-host-disease (aGVHD). CsA of 3 mg/kg/d was continuously given by i.v. infusion, and then 6 mg/kg/d by oral. The blood CsA concentration was 200-300 ng/ml. MTX was given at the dosage of 15 mg/m2 on d 1 and 10 mg/m2 on d 3, 6,9 or 11. MMF was given at the dosage of 0.25-0.5 g/d from day 0 to day 120. Prostaglandin E1 was given to prevent the hepatic veno-occlusive disease (VOD), Ganciclovir was used to prevent CMV infection until the CMV antigenemia became negative. Results Analysis of DNA short tandem repeats showed total en graftment of donor marrow after transplantation in all cases. The median time w hen granulocyte exceeded 0.5×109/L was 14.5 (13-18) days, platelets exceed ed 20×109/L was 16 (14 -23) days. The acute GVHD grade Ⅱ-Ⅳ occurred in 2 of 6 (33.3%) patients. There were 3 cases with chronic GVHD and none of them developed with the extensive chronic GVHD. All patients were alive in disease- free situation now with median follow-up 412 (187-1338) days. Conc lusion URD-BMT is an effective method for the treatment of childh ood leukemia.

目的 评价非亲缘异基因骨髓移植 (URD BMT)治疗儿童急性和慢性白血病的临床疗效。方法  6例白血病患儿 ,其中慢性髓系白血病 2例 ,急性淋巴细胞白血病 3例 (第 1次完全缓解 ) ,急性早幼粒细胞白血病 1例 (第 2次完全缓解 ) ,由台湾慈济骨髓捐赠中心提供无关供者骨髓。预处理方案为马利兰 +环磷酰胺 (Bu/Cy2 )方案 ,急性移植物抗宿主病 (aGVHD)预防为霉酚酸酯(MMF)、环孢菌素A(CsA)加氨甲喋呤 (MTX)联合方案 ;以前列素E1预防肝静脉闭塞病 (VOD) ,以巨细胞病毒 (CMV)抗原血症监测和更昔洛韦预防CMV病。供、受者间HLA基因位点型全相合 3例 ,1个基因位点型不合 2例 ,2个基因位点型不合 1例。结果  6例患儿经DNA短串联重复序列多态性分析证明为供髓植入 ,中性粒细胞 >0 5× 10 9/L的中位天数为 14 5 (13~ 18)d ,血小板 >2 0×10 9/L的中位天数为 16 (11~ 2 3)d。发生Ⅱ~Ⅳ度aGVHD 2例 (33% ) ,局限性慢性移植物抗宿主病(cGVHD) 3例 ,未发生广泛性cGVHD。中位随访时间 4 12 ...

目的 评价非亲缘异基因骨髓移植 (URD BMT)治疗儿童急性和慢性白血病的临床疗效。方法  6例白血病患儿 ,其中慢性髓系白血病 2例 ,急性淋巴细胞白血病 3例 (第 1次完全缓解 ) ,急性早幼粒细胞白血病 1例 (第 2次完全缓解 ) ,由台湾慈济骨髓捐赠中心提供无关供者骨髓。预处理方案为马利兰 +环磷酰胺 (Bu/Cy2 )方案 ,急性移植物抗宿主病 (aGVHD)预防为霉酚酸酯(MMF)、环孢菌素A(CsA)加氨甲喋呤 (MTX)联合方案 ;以前列素E1预防肝静脉闭塞病 (VOD) ,以巨细胞病毒 (CMV)抗原血症监测和更昔洛韦预防CMV病。供、受者间HLA基因位点型全相合 3例 ,1个基因位点型不合 2例 ,2个基因位点型不合 1例。结果  6例患儿经DNA短串联重复序列多态性分析证明为供髓植入 ,中性粒细胞 >0 5× 10 9/L的中位天数为 14 5 (13~ 18)d ,血小板 >2 0×10 9/L的中位天数为 16 (11~ 2 3)d。发生Ⅱ~Ⅳ度aGVHD 2例 (33% ) ,局限性慢性移植物抗宿主病(cGVHD) 3例 ,未发生广泛性cGVHD。中位随访时间 4 12 (187~ 1338)d ,全部患儿均无病生存。结论非亲缘异基因骨髓移植是治疗儿童急性和慢性白血病的有效方法。

 
<< 更多相关文摘    
图标索引 相关查询

 


 
CNKI小工具
在英文学术搜索中查有关allogeneic bone的内容
在知识搜索中查有关allogeneic bone的内容
在数字搜索中查有关allogeneic bone的内容
在概念知识元中查有关allogeneic bone的内容
在学术趋势中查有关allogeneic bone的内容
 
 

CNKI主页设CNKI翻译助手为主页 | 收藏CNKI翻译助手 | 广告服务 | 英文学术搜索
版权图标  2008 CNKI-中国知网
京ICP证040431号 互联网出版许可证 新出网证(京)字008号
北京市公安局海淀分局 备案号:110 1081725
版权图标 2008中国知网(cnki) 中国学术期刊(光盘版)电子杂志社